MannKind (MNKD) News Today

MannKind Co. (NASDAQ:MNKD - Free Report) - Stock analysts at Leerink Partnrs issued their Q3 2024 earnings per share (EPS) estimates for MannKind in a note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid forecasts that the biopharmaceutical company will post earn

Leerink Partners began coverage on shares of MannKind in a research report on Monday. They issued an "outperform" rating and a $8.00 price objective on the stock.

MannKind Co. (NASDAQ:MNKD - Get Free Report) insider Stuart A. Tross sold 25,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.26, for a total value of $156,500.00. Following the transaction, the insider now directly owns 1,022,191 shares of the company's stock, valued at approximately $6,398,915.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

MannKind Co. (NASDAQ:MNKD - Get Free Report) insider Stuart A. Tross sold 80,000 shares of MannKind stock in a transaction on Friday, August 30th. The shares were sold at an average price of $6.33, for a total transaction of $506,400.00. Following the transaction, the insider now owns 1,047,191 shares in the company, valued at approximately $6,628,719.03. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

MannKind Co. (NASDAQ:MNKD - Get Free Report) EVP Steven B. Binder sold 5,055 shares of the stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $5.94, for a total value of $30,026.70. Following the completion of the sale, the executive vice president now owns 1,075,026 shares of the company's stock, valued at $6,385,654.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

MannKind (NASDAQ:MNKD) Trading Up 7.6% Following Analyst Upgrade

MannKind (NASDAQ:MNKD) Hits New 52-Week High on Analyst Upgrade

Shares of MannKind Co. (NASDAQ:MNKD - Get Free Report) have received an average recommendation of "Buy" from the five brokerages that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year price

Oppenheimer boosted their price target on shares of MannKind from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Wednesday.

MannKind (NASDAQ:MNKD) Stock Price Up 7.4%

MannKind Co. (NASDAQ:MNKD - Free Report) - Investment analysts at Leerink Partnrs raised their Q4 2024 earnings per share estimates for shares of MannKind in a research report issued to clients and investors on Wednesday, August 7th. Leerink Partnrs analyst T. Smith now forecasts that the biophar

MannKind Co. (NASDAQ:MNKD - Free Report) - Investment analysts at Leerink Partnrs increased their FY2025 earnings estimates for shares of MannKind in a note issued to investors on Wednesday, August 7th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will post ea

Vanguard Group Inc. trimmed its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 0.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,140,709 shares of the biopharmaceutical company's stock after selling 107,899 shares during t

MannKind (NASDAQ:MNKD) will be releasing earnings before the market opens on Wednesday, August 7, Zacks reports.

SG Americas Securities LLC reduced its position in MannKind Co. (NASDAQ:MNKD - Free Report) by 90.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,141 shares of the biopharmaceutical company's stock after selling 1

BNP Paribas Financial Markets decreased its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 60.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 146,658 shares of the biopharmace

Susquehanna Fundamental Investments LLC acquired a new stake in MannKind Co. (NASDAQ:MNKD - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 99,267 shares of the biopharmaceutical company's stock, valued at a

MannKind (NASDAQ:MNKD) Reaches New 52-Week High at $5.77

MannKind (NASDAQ:MNKD) Shares Up 4.9%

180 Wealth Advisors LLC increased its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 12.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,942,210 shares of the biopharmaceutical company's stock after purchasing

MannKind (NASDAQ:MNKD) Trading 5.1% Higher

Parkman Healthcare Partners LLC boosted its holdings in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 20.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,498,624 shares of the biopharmaceutical